Ani Pharmaceuticals (ANIP) Receivables - Other (2014 - 2022)

Ani Pharmaceuticals has disclosed Receivables - Other across 5 years of filings, most recently posting $5.0 million for Q4 2022.

• Receivables - Other for Q4 2022 came in at $5.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $5.0 million (changed N/A YoY), and the FY2022 annual result was $5.0 million, changed N/A from the prior year.
• Receivables - Other came in at $5.0 million for Q4 2022 at Ani Pharmaceuticals, up from $100000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $5.0 million in Q4 2022 to a low of $14000.0 in Q3 2018.
• The 4-year median for Receivables - Other is $100000.0 (2018), against an average of $581400.0.
• Peak annual rise in Receivables - Other reached 614.29% in 2019, while the deepest fall reached 0.0% in 2019.
• Ani Pharmaceuticals' Receivables - Other stood at $100000.0 in 2018, then changed by 0.0% to $100000.0 in 2019, then changed by 0.0% to $100000.0 in 2020, then surged by 4900.0% to $5.0 million in 2022.
• The last three Receivables - Other figures came in at $5.0 million (Q4 2022), $100000.0 (Q3 2020), and $100000.0 (Q2 2020), per Business Quant data.